ClinicalTrials.gg
CompletedNCT00436553Updated Apr 19, 2011Results posted

Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization

A Phase 3 interventional study of Verteporfin Photodynamic Therapy and Ranibizumab in Macular Degeneration and Choroidal Neovascularization, sponsored by Novartis. Completed at 43 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2011-04-19.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
321
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing verteporfin in Macular Degeneration — none open to participants now, none under way, none of them phase 3. Verteporfin · Macular Degeneration.

Enrollment
4th of 17
321 · median 60
Started
2007
with 4 others
Phase 3
4 of 18
none open now
Registered
9th of 18
by date
Lead sponsor
4 of 18
Novartis

Among the 18 studies testing verteporfin in Macular Degeneration, this one is the 4th largest by enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2007, is one of 4 in phase 3, and was the 9th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

None of the 18 studies testing verteporfin in Macular Degeneration is open now. The open studies under Macular Degeneration, anywhere →

About verteporfin

Verteporfin: first FDA approval 2000 (VISUDYNE), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing verteporfin in Macular Degeneration as a file.
02

Study summary

This study evaluated the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity and anatomic outcomes compared to ranibizumab monotherapy and the durability of response observed in patients with choroidal neovascularization secondary to age-related macular degeneration.

03

Conditions studied

  • Macular Degeneration
  • Choroidal Neovascularization

Keywords

  • Age-related macular degeneration; AMD
  • choroidal neovascularization
  • verteporfin
  • ranibizumab
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects of either gender age 50 years or older
  • Subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD)

Exclusion criteria

Exclusion Criteria:

  • Choroidal neovascularization due to causes other than AMD
  • Prior treatment for neovascular AMD in the study eye

Other protocol-defined inclusion/exclusion criteria may apply

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
321 participants (actual)

Study arms

  • Experimental
    Verteporfin With Standard Fluence Rate Plus Ranibizumab

    Patients received three consecutive monthly ranibizumab injections on Day 1 and at Months 1 and 2, and thereafter as needed at intervals of at least 30 days based on retreatment criteria. These patients also received verteporfin photodynamic therapy (PDT) with standard fluence (SF) rate on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and choroidal neovascularization (CNV) leakage assessed by fluorescein angiography (FA). Patients received sham intravitreal injections for the first 12 months if retreatment with ranibizumab was not warranted based on the retreatment criteria.

    Drug: Verteporfin Photodynamic Therapy · Drug: Ranibizumab · Drug: Ranibizumab Placebo

  • Active comparator
    Ranibizumab Monotherapy

    Patients received monthly ranibizumab injections for 12 months and thereafter as needed based on the retreatment criteria. These patients were also administered verteporfin placebo infusion with sham PDT on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. Retreatments were determined based on study specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and choroidal neovascularization (CNV) leakage assessed by fluorescein angiography (FA).

    Drug: Ranibizumab · Drug: Verteporfin Placebo

  • Experimental
    Verteporfin With Reduced Fluence Rate Plus Ranibizumab

    Patients received three consecutive monthly ranibizumab injections on Day 1 and at Months 1 and 2, and thereafter as needed at intervals of at least 30 days based on retreatment criteria. These patients also received verteporfin PDT with reduced fluence (RF) rate on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and choroidal neovascularization (CNV) leakage assessed by fluorescein angiography (FA). Patients received sham intravitreal injections for the first 12 months if retreatment with ranibizumab was not warranted based on the retreatment criteria.

    Drug: Verteporfin Photodynamic Therapy · Drug: Ranibizumab · Drug: Ranibizumab Placebo

Interventions

  • After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 (Standard Fluence rate) or 25 J/cm\^2 (Reduced Fluence rate) to the study eye, begun 15 minutes after the start of the infusion.

    Also known as: Visudyne

  • Ranibizumab 0.5 mg administered as an intravitreal injection.

    Also known as: Lucentis

  • DrugVerteporfin Placebo

    To maintain masking, as a placebo for verteporfin photodynamic therapy, patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.

  • DrugRanibizumab Placebo

    To maintain masking, patients in the combination groups received sham intravitreal injections whenever retreatment with active Ranibizumab was not warranted based on the retreatment algorithm.

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 12

    BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increase in the VA score indicates improvement in visual acuity.

    Time frame: Baseline and Month 12

  2. Percent of Patients With a Treatment-free Interval of at Least 3 Months Following the Month 2 Visit

    The number of patients with a ranibizumab treatment-free interval, ie, no active ranibizumab treatments for at least 3 months duration (at least 2 consecutive monthly visits), anytime following the Month 2 ranibizumab treatment. Only active ranibizumab treatments were considered.

    Time frame: Month 2 up to Month 11

Secondary outcomes

  1. Change From Baseline in Total Area of Leakage of the Study Eye at Month 12

    Total area of leakage of the study eye was assessed at the Central Reading Center (CRC) using Fluorescein angiography (FA).

    Time frame: Baseline and Month 12

  2. Percentage of Patients With Fluorescein Leakage in the Study Eye at Month 12

    The percentage of patients with leakage of the study eye was assessed at the Central Reading Center (CRC) using Fluorescein angiography (FA).

    Time frame: Month 12

  3. Change From Baseline in Central Retinal Thickness at Month 12

    Optical coherence tomography was performed in the study eyes and the evaluations of the images were performed by the central reading center.

    Time frame: Baseline and Month 12

07

Results

Posted Apr 19, 2011
Limitations and caveats
Shorten the study duration from 24 months to 12 months based on results of the European combination study MONT BLANC (CBPD952A2309).

Participant flow

Participant flow — Overall Study
MilestoneVerteporfin SF + RanibizumabVerteporfin RF + RanibizumabRanibizumab Monotherapy
Started104105112
Completed9193102
Not completed131210
Withdrew: Adverse event434
Withdrew: Death313
Withdrew: Lost to follow-up020
Withdrew: Protocol violation100
Withdrew: Withdrawal by subject563

Outcome measures

PrimaryMean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 12

BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increase in the VA score indicates improvement in visual acuity.

Time frame:
Baseline and Month 12
Reported as:
Mean · Letters
Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 12
LettersVerteporfin SF + RanibizumabVerteporfin RF + RanibizumabRanibizumab Monotherapy
Baseline53.7 ± 13.5254.6 ± 12.7854.8 ± 13.55
Month 1259.0 ± 17.4759.0 ± 18.0363.0 ± 18.88
Change from baseline5.3 ± 15.664.4 ± 15.478.1 ± 15.09
SecondaryChange From Baseline in Total Area of Leakage of the Study Eye at Month 12

Total area of leakage of the study eye was assessed at the Central Reading Center (CRC) using Fluorescein angiography (FA).

Time frame:
Baseline and Month 12
Reported as:
Mean · mm^2
Change From Baseline in Total Area of Leakage of the Study Eye at Month 12
mm^2Verteporfin SF + RanibizumabVerteporfin RF + RanibizumabRanibizumab Monotherapy
Baseline6.654 ± 4.09566.211 ± 5.06186.931 ± 4.6473
Month 123.472 ± 4.23403.024 ± 4.01883.177 ± 4.9930
Change from Baseline-3.182 ± 4.9729-3.187 ± 5.9744-3.753 ± 5.8005
SecondaryPercentage of Patients With Fluorescein Leakage in the Study Eye at Month 12

The percentage of patients with leakage of the study eye was assessed at the Central Reading Center (CRC) using Fluorescein angiography (FA).

Time frame:
Month 12
Reported as:
Number · Percentage of participants
Percentage of Patients With Fluorescein Leakage in the Study Eye at Month 12
Percentage of participantsVerteporfin SF + RanibizumabVerteporfin RF + RanibizumabRanibizumab Monotherapy
Percentage of Patients With Fluorescein Leakage in the Study Eye at Month 1258.2 ± 054.5 ± 041.8 ± 0
SecondaryChange From Baseline in Central Retinal Thickness at Month 12

Optical coherence tomography was performed in the study eyes and the evaluations of the images were performed by the central reading center.

Time frame:
Baseline and Month 12
Reported as:
Mean · micrometer
Change From Baseline in Central Retinal Thickness at Month 12
micrometerVerteporfin SF + RanibizumabVerteporfin RF + RanibizumabRanibizumab Monotherapy
Baseline444.654 ± 137.7119446.638 ± 129.5482456.824 ± 153.4270
Month 12292.921 ± 79.2733305.719 ± 80.4508284.586 ± 75.4892
Change from Baseline-151.733 ± 135.6200-140.919 ± 128.0741-172.238 ± 166.6691
PrimaryPercent of Patients With a Treatment-free Interval of at Least 3 Months Following the Month 2 Visit

The number of patients with a ranibizumab treatment-free interval, ie, no active ranibizumab treatments for at least 3 months duration (at least 2 consecutive monthly visits), anytime following the Month 2 ranibizumab treatment. Only active ranibizumab treatments were considered.

Time frame:
Month 2 up to Month 11
Reported as:
Number · Percent of participants
Percent of Patients With a Treatment-free Interval of at Least 3 Months Following the Month 2 Visit
Percent of participantsVerteporfin SF + RanibizumabVerteporfin RF + Ranibizumab
Percent of Patients With a Treatment-free Interval of at Least 3 Months Following the Month 2 Visit92.6 (85.4 to 97.0)83.5 (74.6 to 90.3)

Adverse events

Collected over Cumulative up to Month 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Verteporfin SF + Ranibizumab—32/104 (30.8%)85/104 (81.7%)
Verteporfin RF + Ranibizumab—29/106 (27.4%)81/106 (76.4%)
Ranibizumab Monotherapy—41/111 (36.9%)87/111 (78.4%)
Most frequent serious events
Showing 10 of 122
Most frequent serious events
EventVerteporfin SF + RanibizumabVerteporfin RF + RanibizumabRanibizumab Monotherapy
Cardiac failure congestiveCardiac disorders2/1042/1066/111
Visual acuity reduced (Study eye)Eye disorders4/1041/1063/111
PneumoniaInfections and infestations2/1043/1064/111
BradycardiaCardiac disorders0/1040/1063/111
Transient ischaemic attackNervous system disorders0/1041/1063/111
Atrial fibrillationCardiac disorders2/1040/1061/111
AstheniaGeneral disorders2/1040/1060/111
Hip fractureInjury, poisoning and procedural complications2/1041/1061/111
Myocardial infarctionCardiac disorders1/1042/1061/111
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1042/1061/111
Most frequent other events
Showing 10 of 45
Most frequent other events
EventVerteporfin SF + RanibizumabVerteporfin RF + RanibizumabRanibizumab Monotherapy
Eye pain (Study eye)Eye disorders22/10414/10614/111
Conjunctival haemorrhage (Study eye)Eye disorders13/10418/10618/111
HypertensionVascular disorders9/10413/10612/111
NasopharyngitisInfections and infestations10/1046/10613/111
Choroidal neovascularisation (Fellow eye)Eye disorders7/10412/1068/111
Macular degeneration (Fellow eye)Eye disorders8/1046/10612/111
Upper respiratory tract infectionInfections and infestations11/10410/1067/111
Myodesopsia (Study eye)Eye disorders2/10411/10610/111
Visual acuity reduced (Study eye)Eye disorders10/1049/1065/111
Lacrimation increased (Study eye)Eye disorders6/1046/10610/111

Baseline characteristics

Age Continuous
Age Continuous(years)Verteporfin SF + RanibizumabVerteporfin RF + RanibizumabRanibizumab MonotherapyTotal
Mean77.5 ± 8.4277.4 ± 8.4877.2 ± 7.9777.3 ± 8.26
Sex: Female, Male
Sex: Female, Male(Participants)Verteporfin SF + RanibizumabVerteporfin RF + RanibizumabRanibizumab MonotherapyTotal
Female645375192
Male405237129
08

Study locations

43 sites
  • Novartis Investigative Site
    Tucson, Arizona 85704, United States
  • Novartis Investigative Site
    Beverly Hills, California 90211, United States
  • Novartis Investigative Site
    Oakland, California 94609, United States
  • Novartis Investigative Site
    Pasadena, California 91105-3153, United States
  • Novartis Investigative Site
    Sacramento, California 95819, United States
  • West Coast Retina Medical Group Inc. - 185 Berry St. Suite 130
    San Francisco, California 94107, United States
  • Novartis Investigative Site
    Santa Ana, California 92705, United States
  • Novartis Investigative Site
    Denver, Colorado 80210, United States
  • Novartis Investigative Site
    Aiea, Hawaii 96701, United States
  • Novartis Investigative Site
    Iowa City, Iowa 52242, United States
  • Novartis Investigative Site
    Wichita, Kansas 67214, United States
  • Novartis Investigative Site
    Lexington, Kentucky 40509, United States
  • Novartis Investigative Site
    Paducah, Kentucky 42001, United States
  • Novartis Investigative Site
    Baltimore, Maryland 21205, United States
  • Novartis Investigative Site
    Grand Rapids, Michigan 49252, United States
  • Novartis Investigative SIte
    Royal Oak, Michigan 48073, United States
  • Novartis Investigative Site
    Williamsburg, Michigan 49690, United States
  • Novartis Investigative Site
    Independence, Missouri 64055, United States
  • Novartis Investigative Site
    St. Louis, Missouri 63110, United States
  • Novartis Investigative Site
    Toms River, New Jersey 08755, United States
  • Novartis Investigative Site
    Lynbrook, New York 11563, United States
  • Novartis Investigative Site
    Rochester, New York 14620, United States
  • Novartis Investigative Site
    Beachwood, Ohio 44122, United States
  • Novartis Investigative Site
    Cincinnati, Ohio 45242, United States
  • Novartis Investigative Site
    Cleveland, Ohio 44195, United States
  • Novartis Investigative Site
    Pittsburgh, Pennsylvania 15213, United States
  • Novartis Investigative Site
    West Mifflin, Pennsylvania 15122, United States
  • Novartis Investigative Site
    West Columbia, South Carolina 29169, United States
  • Novartis Investigative Site
    Rapid City, South Dakota 57701, United States
  • Novartis Investigative Site
    Kingsport, Tennessee 37660, United States
  • Novartis Investigative Site
    Knoxville, Tennessee 37909, United States
  • Novartis Investigative Site
    Austin, Texas 78705, United States
  • Novartis Investigative Site
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    Fairfax, Virginia 22031, United States
  • Novartis Investigative Site
    Richmond, Virginia 23226, United States
  • Novartis Investigative Site
    Milwaukee, Wisconsin 53226, United States
  • Novartis Investigative Site
    Edmonton, Alberta T5H OX5, Canada
  • Novartis Investigative Site
    Vancouver, British Columbia V5Z 3N9, Canada
  • Novartis Investigative Site
    Halifax, Nova Scotia B3H 2Y6, Canada
  • Ivey Eye Institute, Dr. Thomas Sheidow
    London, Ontario N6A 4G5, Canada
  • Novartis Investigative Site
    London, Ontario N6A 4G5, Canada
  • Novartis Investigative Site
    Ottawa, Ontario KIH 8L6, Canada
  • Novartis Investigative Site
    Montreal, Quebec H2L 4MI, Canada
09

References and documents

Publications

  • Kaiser PK, Boyer DS, Cruess AF, Slakter JS, Pilz S, Weisberger A; DENALI Study Group. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology. 2012 May;119(5):1001-10. doi: 10.1016/j.ophtha.2012.02.003. Epub 2012 Mar 22. PubMed 22444829 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2007
First posted
Feb 19, 2007
Start
Feb 2007
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Results first posted
Apr 19, 2011
Last update
Apr 19, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00436553
Lead sponsor
Novartis
First posted
Feb 19, 2007
Start date
Feb 2007
Primary completion
Oct 2009
Completion
Oct 2009
Results posted
Apr 19, 2011
Last update
Apr 19, 2011

Study contacts

Novartis
study chair · Novartis
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Verteporfin

Start the discussion